BFRIW Biofrontera Inc. - Warrants
0.0200USD-0.50%Mkt Cap: —P/E: —6d ago
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL l…
Industry Peers
Biotechnology$128.08BUSDP/E 29.4
$78.44BUSD
$76.40BUSDP/E 18.4
$57.03BUSDP/E 37.3
$58.08BUSDP/E 35.4
$42.24BUSDP/E 18.0
$43.05BUSD
$41.41BUSDP/E 65.1
$32.80BUSDP/E 30.2
$30.03BUSDP/E 37.8
$25.10BUSD
$23.93BUSD
$22.99BUSDP/E 14.5
$22.27BUSDP/E 30.7
$22.54BUSDP/E 28.9
$22.22BUSD
$15.03BUSDP/E 17.5
$15.01BUSDP/E 15.8
$14.48BUSDP/E 18.4
$14.32BUSD
Key Statistics
Company
Market Cap—
Enterprise Value—
Revenue (TTM)46.17M USD
Gross Profit30.74M USD
Net Income (TTM)-10.54M USD
Revenue/Share3.92 USD
Last Price0.0200 USD
Fiscal Year End—
MR Quarter—
Employees84
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.03
EPS (TTM)-1.30
EPS (Forward)—
52W Range
0.02000% of range0.0660
52W High0.0660 USD
52W Low0.0200 USD
Profitability
Gross Margin73.71%
Oper. Margin-4.37%
EBITDA Margin-12.93%
Profit Margin-25.26%
ROE-100.53%
ROA-36.89%
Growth
Revenue Growth32.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-13.36M USD
CapEx (TTM)2.00K USD
FCF Margin-16.45%
FCF Yield—
Net Debt2.84M USD
Net Debt/EBITDA-0.48
Balance Sheet
Debt/Equity0.59
Current Ratio1.18
Quick Ratio1.00
Book Value/Sh0.42 USD
Cash/Share0.31 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float11.82M
Insiders—
Institutions—
Technical
SMA 50—
SMA 200—
Beta0.88
S&P 52W Chg15.78%
Avg Vol (30d)5.43K
Avg Vol (10d)—
Technical Indicators
RSI (14)39.9
MACD-0.0042
MACD Signal-0.0040
MACD Hist.-0.0002
BB Upper0.0325 USD
BB Middle0.0238 USD
BB Lower0.0152 USD
BB Width72.68%
ATR (14)0.0045 USD
Vol Ratio (20d)0.02x